ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00263965
Recruitment Status : Terminated (The development program has been terminated)
First Posted : December 12, 2005
Last Update Posted : March 17, 2008
Information provided by:

Brief Summary:
This is a 16-week randomized, double-blind, parallel-group, multi-center, placebo- and active- (metformin 1.5 g) controlled study of tesaglitazar (1 mg) in patients with type 2 diabetes. After a 1-week enrollment period, a 3 week placebo single blind run in period and 1-week placebo single-blind baseline measurement period, the patients will be given the investigational product for 16 weeks in a double blind fashion. Metformin will be titrated up during the first 3 weeks of the double-blind period. The total study duration, including enrollment, run-in, randomized treatment and follow-up, is 29 weeks.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: Tesaglitazar Drug: Metformin Behavioral: Dietary and lifestyle modification counseling Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 105 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 16-Week Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo- and Active- (Metformin) Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
Study Start Date : August 2005
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy
Drug Information available for: Metformin

Primary Outcome Measures :
  1. Whole-body insulin sensitivity by assessing the M value during high (80 mU/m2/min) insulin level euglycemic hyperinsulinemic clamp.

Secondary Outcome Measures :
  1. Hepatic and peripheral insulin sensitivity by assessing the M value during low (20 mU/m2/min) insulin level euglycemic hyperinsulinemic clamp.
  2. Basal hepatic glucose output measured by dideuterated glucose in the fasting state and during low insulin level clamp.
  3. Plasma profile of glucose, insulin and lipids after a mixed meal
  4. Calculated insulin secretion
  5. Liver oxidation after a mixed meal
  6. Energy expenditure and substrate metabolism by indirect calorimetry
  7. Body composition using DXA-scan, abdominal fat distribution using magnetic resonance imaging, liver fat and muscle fat content using magnetic resonance spectroscopy
  8. Waist and hip circumference
  9. Laboratory efficacy variables (lipids, inflammatory marker and adipose tissue hormones)
  10. Safety and tolerability of tesaglitazar in patients with type 2 diabetes.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provision of a written informed consent
  • Men or women who are 30-70 years of age
  • Female patients: postmenopausal, hysterectomized
  • Diagnosed with type 2 diabetes
  • Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents

Exclusion Criteria:

  • Type 1 diabetes
  • New York Heart Association heart failure Class III or IV
  • Treatment with chronic insulin
  • History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
  • History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
  • Creatinine levels above twice the normal range
  • Creatine kinase above 3 times the upper limit of normal
  • Received any investigational product in other clinical studies within 12 weeks
  • Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00263965

Research Site
Helsinki, Finland
Research Site
Pisa, Italy
United Kingdom
Research Site
Oxford, United Kingdom
Sponsors and Collaborators
Study Director: AstraZeneca Galida Medical Science Director, MD AstraZeneca Identifier: NCT00263965     History of Changes
Other Study ID Numbers: D6160C09999
EudraCT No 2004-000350-24
First Posted: December 12, 2005    Key Record Dates
Last Update Posted: March 17, 2008
Last Verified: March 2008

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Insulin Resistance
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs